Table 2.

Association between IL1RN variants and prostate cancer risk (N = 1,012)

SNPControls, n (%)Case, n (%)OR (95% CI)*P
rs3087263
    GG419 (82.8)433 (85.6)1.00
    AG83 (16.4)69 (13.6)0.80 (0.57-1.14)0.22
    AA4 (0.8)4 (0.8)0.96 (0.24-3.88)0.96
rs380092
    AA201 (39.8)208 (41.1)1.00
    AT214 (42.4)213 (42.1)1.07 (0.74-1.54)0.72
    TT90 (17.8)85 (16.8)1.12 (0.76-1.64)0.56
rs4252019
    CC341 (67.4)344 (68.0)1.00
    CT141 (27.9)141 (27.9)0.99 (0.74-1.31)0.92
    TT24 (4.7)21 (4.2)0.85 (0.45-1.62)0.63
rs579543
    CC301 (59.5)291 (57.5)1.00
    CT177 (35.0)180 (35.6)0.95 (0.73-1.24)0.95
    TT28 (5.5)35 (6.9)0.77 (0.46-1.30)0.68
rs315951
    CC234 (46.3)231 (45.7)1.00
    CG219 (43.3)218 (43.1)1.01 (0.78-1.32)0.95
    GG53 (10.5)57 (11.3)1.09 (0.72-1.66)0.68
rs4252041
    CC474 (93.7)470 (93.1)1.00
    CT32 (6.3)33 (6.5)1.04 (0.63-1.73)0.88
    TT0 (0)2 (0.4)
rs9005
    GG254 (50.2)268 (53.0)1.00
    AG206 (40.7)206 (40.7)0.95 (0.73-1.23)0.68
    AA46 (9.1)32 (6.3)0.66 (0.41-1.07)0.09
Multimarker haplotype
rs3087263, rs579543:GG
    036 (7.1)29 (5.7)1.00
    1 copy182 (36.0)178 (35.2)1.22 (0.72-2.08)0.46
    2 copies288 (56.9)299 (59.1)1.30 (0.77-2.19)0.32
rs380092, rs579543:AG
    0201 (39.7)193 (38.1)1.00
    1 copy238 (47.0)225 (44.5)0.99 (0.75-1.31)0.94
    2 copies67 (13.2)88 (17.4)1.38 (0.94-2.03)0.10
rs4252019, rs579543:CG
    096 (19.0)89 (17.6)1.00
    1 copy246 (48.6)237 (46.8)1.04 (0.74-1.46)0.84
    2 copies164 (32.4)180 (36.6)1.18 (0.83-1.70)0.36
rs579543, rs315951:GG
    047 (9.3)34 (6.7)1.00
    1 copy209 (41.3)211 (41.7)1.41 (0.87-2.29)0.16
    2 copies250 (49.4)261 (51.6)1.46 (0.91-2.34)0.12
  • * Adjusted for age, racial/ethnic group, and institution.